Protocol Ledger

NCT05479994 · Phase II · ACTIVE NOT RECRUITING

Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Interventional Phase II clinical trial protocol NCT05479994 sponsored by BeiGene in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-10-25 Enrollment: 100 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05479994
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)100 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05479994
Protocol FieldVerified Registry Value
NCT IdentifierNCT05479994
Consolidated Lead SponsorBeiGene
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment100 participants (ACTUAL)
Registered Start Date2022-10-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05479994
Hospital Research SiteLocationSite Profile
Peking University Third HospitalBeijing, ChinaOpen Hospital Dossier ->
Beijing HospitalBeijing, ChinaOpen Hospital Dossier ->
Fujian Cancer HospitalFuzhou, ChinaOpen Hospital Dossier ->
Lanzhou University Second HospitalLanzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI